STOCK TITAN
  1. Home
  2. News
  3. ESPR

Esperion Therapeutics, Inc. - ESPR STOCK NEWS

Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.

Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.

In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.

Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.

The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.

News

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Rhea-AI Summary
Esperion (ESPR) receives FDA approval for expanded labels for NEXLETOL and NEXLIZET, broadening treatable population to 70 million in the U.S. The approvals are based on positive CLEAR Outcomes data, allowing for cardiovascular risk reduction and LDL-C lowering in primary and secondary prevention patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
fda approval
-
News

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

Rhea-AI Summary
Daiichi Sankyo and Esperion Therapeutics receive positive CHMP opinions for bempedoic acid and bempedoic acid / ezetimibe FDC, aiming to reduce LDL-C and cardiovascular risk in Europe. The European Commission is expected to make a decision in 1H 2024. The opinions are based on Phase 3 CLEAR Outcomes trial, showing a 13% reduction in major adverse cardiovascular events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
-
News

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Esperion (ESPR) reports strong financial growth in FY23 with U.S. net product revenue up 40% Y/Y to $78.3 million. Q4 U.S. net product revenue grew 39% Y/Y to $20.8 million. The company resolved litigation, receiving $100 million and potential cost savings. Positive interactions with FDA and EMA for cardiovascular indications. Recent equity offering raised $97.8 million. FDA approved updated LDL-C indication for NEXLETOL and NEXLIZET. Financial results show total revenue growth of 54% Y/Y to $116.3 million in FY23. Operating expenses for 2024 expected to be $225-245 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.27%
Tags
earnings
News

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Esperion (ESPR) granted 66 new employees 204,900 restricted stock units (RSUs) under the 2017 Inducement Equity Incentive Plan. Each RSU will vest over time, subject to continued employment. Esperion focuses on developing medicines for cardiovascular diseases, aiming to improve patient outcomes by lowering LDL-cholesterol levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
News

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

Rhea-AI Summary
Esperion (NASDAQ: ESPR) to report Q4 and full year 2023 financial results on February 27, 2024. Webcast to discuss financial results and business updates. Esperion focuses on innovative medicines for cardiovascular and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
-
News

RFK, Esperion Therapeutics Announce 2024 Promotional Schedule

Rhea-AI Summary
RFK Racing and Esperion Therapeutics have announced a promotional schedule for the 2024 season, featuring a four-race slate highlighting NEXLIZET and NEXLETOL, used to reduce LDL-cholesterol. The season debut comes in the first race at Richmond this spring, with additional races at North Wilkesboro, Pocono, and Talladega. The partnership between RFK and Esperion will promote a myriad of campaigns and initiatives, including National Wear Red Day, American Heart Month, Stress Awareness Month, Women’s Health Awareness Month, Men’s Health Awareness Month, a Wellness Walk, Cholesterol Education Month, World Heart Day, National Health Education Week, and Family Health History Day. NEXLIZET should not be used in patients who have had a previous allergic reaction to ezetimibe. NEXLIZET and NEXLETOL can increase levels of uric acid in the blood which can lead to gout. Esperion's CEO expressed excitement about the robust marketing campaign and the race schedule, highlighting the combined efforts on promoting cholesterol awareness and various additional health awareness months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
News

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary
Esperion Therapeutics, Inc. announced the closing of its underwritten public offering of 65,205,000 shares of its common stock, raising approximately $97.8 million. The company plans to use the net proceeds for ongoing commercialization efforts, research and clinical development, working capital, capital expenditures, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
offering
-
News

Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock

Rhea-AI Summary
Esperion Therapeutics, Inc. announced the pricing of its underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, with expected gross proceeds of approximately $85.1 million. The offering is expected to close on January 23, 2024, and the net proceeds will fund ongoing commercialization efforts, research and clinical development, working capital, capital expenditures, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
offering
-
News

Esperion Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Esperion Therapeutics, Inc. has announced the commencement of an underwritten public offering of shares of its common stock, with the underwriters granted a 30-day option to purchase additional shares. The company plans to use the net proceeds to fund ongoing commercialization efforts, research and clinical development, working capital, capital expenditures, and general corporate purposes. The offering is subject to market conditions and the actual size or terms are uncertain. Jefferies LLC is acting as the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
offering
News

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

Rhea-AI Summary
Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) announced a $125 million amendment to their collaboration, including a $100 million payment to Esperion and expansion of collaboration in Europe and other territories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.23%
Tags
none

FAQ

What is the current stock price of Esperion Therapeutics (ESPR)?

The current stock price of Esperion Therapeutics (ESPR) is $2.52 as of November 22, 2024.

What is the market cap of Esperion Therapeutics (ESPR)?

The market cap of Esperion Therapeutics (ESPR) is approximately 476.5M.

What is Esperion Therapeutics, Inc.?

Esperion Therapeutics, Inc. is a pharmaceutical company specializing in developing first-in-class, oral therapies that lower low-density lipoprotein cholesterol (LDL-C).

What products does Esperion offer?

Esperion offers NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to lower elevated LDL-C levels.

What recent achievements has Esperion made?

Esperion recently received broad new label expansions for NEXLETOL and NEXLIZET, covering cardiovascular risk reduction and expanded LDL-C lowering for both primary and secondary prevention patients.

What is ETC-1002?

ETC-1002 is Esperion's lead product candidate, an inhibitor of ATP citrate lyase, an enzyme involved in cholesterol biosynthesis.

What is the significance of the CLEAR Outcomes trial?

The CLEAR Outcomes trial demonstrated the efficacy and safety of bempedoic acid, a key component in NEXLETOL and NEXLIZET, in reducing cardiovascular events in high-risk patients.

Who can benefit from Esperion's medications?

Over 70 million patients, including those with elevated LDL-C levels and those at high risk of cardiovascular events, can benefit from Esperion's medications.

What partnerships does Esperion have?

Esperion has partnered with companies like Otsuka to develop and commercialize bempedoic acid in various regions, including Japan.

What are the common side effects of NEXLETOL and NEXLIZET?

Common side effects include upper respiratory tract infection, muscle spasms, hyperuricemia, and back pain, among others.

How does Esperion support its patients?

Esperion enhances patient support programs and works with payers to improve access to its medications.

What are Esperion's future plans?

Esperion plans to continue clinical development, expand into new markets, and address unmet medical needs in cardiovascular care.

Stock ESPR logo
Esperion Therapeutics, Inc.

Nasdaq:ESPR

ESPR Rankings

#3162 Ranked by Market Cap
N/A Ranked by Dividends

ESPR Stock Data

476.49M
196.07M
0.5%
66.33%
17.05%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
ANN ARBOR